Toxicity Clinical Trials

5 recruiting

Toxicity Trials at a Glance

139 actively recruiting trials for toxicity are listed on ClinicalTrialsFinder across 6 cities in 37 countries. The largest study group is Not Applicable with 48 trials, with the heaviest enrollment activity in Toronto, New York, and Amsterdam. Lead sponsors running toxicity studies include Odense University Hospital, Indiana University, and Erasmus Medical Center.

Treatments under study

About Toxicity Clinical Trials

Looking for clinical trials for Toxicity? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Toxicity trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Toxicity clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 139 trials

Recruiting

Financial Toxicity in Patients With Resected Soft Tissue and Bone Sarcomas

Financial ToxicityBone Sarcomas
M.D. Anderson Cancer Center100 enrolled1 locationNCT07215611
Recruiting

Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy

CancerQuality of LifeDistress, Emotional+4 more
Taipei Veterans General Hospital, Taiwan200 enrolled1 locationNCT06461780
Recruiting
Not Applicable

Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy

NeuropathyPeripheral NeuropathyPeripheral Neuropathy Due to Chemotherapy+1 more
Ka-Wai Ho60 enrolled2 locationsNCT07095998
Recruiting
Phase 2

Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium

Anticholinergic Toxicity
Washington University School of Medicine42 enrolled1 locationNCT06399679
Recruiting
Not Applicable

Effect of a Novel Topical Composition on the Incidence of Severe Oral Mucositis in Head & Neck Cancer Radiated Patients and Quality of Life Assessed by PROMs.

PainHead and Neck CancerQuality of Life+6 more
Mucosa Innovations, S.L.63 enrolled1 locationNCT05635929
Recruiting
Not Applicable

Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy

CardiotoxicityAnthracycline-induced Cardiotoxicity
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)93 enrolled1 locationNCT07528586
Recruiting
Not Applicable

Assessment of the Impact of Increased Production of Reactive Oxygen Species Produced During Repeated Sessions of Hyperbaric Oxygen Therapy in Patients Undergoing Radiotherapy for Neoplasia, on the Occurrence of DNA Damage

MalignancyGenotoxicityHyperbaric Oxygen
University Hospital, Angers60 enrolled1 locationNCT06999785
Recruiting
Phase 4

The STOP-MED CTRCD Trial

Heart FailureCancerCardiotoxicity+2 more
Dinesh Thavendiranathan335 enrolled14 locationsNCT06183437
Recruiting
Not Applicable

In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors

Cancer SurvivorsCardiotoxicityCardiovascular Toxicity Induced by Antitumoral Drugs
University College, London10 enrolled3 locationsNCT06778122
Recruiting
Not Applicable

Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences

Skin Toxicity
University of Miami40 enrolled1 locationNCT04650256
Recruiting

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

Heart FailureBreast NeoplasmsCardiotoxicity+1 more
University Hospital, Caen600 enrolled1 locationNCT07191730
Recruiting
Not Applicable

Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression

Quality of LifeOligometastatic DiseaseToxicity Due to Radiotherapy+1 more
Robert Olson598 enrolled13 locationsNCT05784428
Recruiting
Phase 2

Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity

Solid TumorsCisplatin Nephrotoxicity
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran46 enrolled1 locationNCT07018622
Recruiting
Phase 2

Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

Ototoxicity, Drug-Induced
Kevin Winthrop105 enrolled5 locationsNCT05730283
Recruiting

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

Breast CancerLiver CancerEsophageal Cancer+35 more
UMC Utrecht8,000 enrolled18 locationsNCT04075305
Recruiting

Curatively Intended Thoracic Reirradiation

Radiotherapy Side EffectLung CancerThoracic Cancer+2 more
University of Aarhus500 enrolled1 locationNCT06950073
Recruiting
Not Applicable

Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy

Sexual DysfunctionRadiation ToxicityDyspareunia+1 more
Indiana University20 enrolled3 locationsNCT06059586
Recruiting
Phase 3

Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases

Radiation ToxicityBrain MetastasasesHigh Grade Glioma (III or IV)+4 more
The Netherlands Cancer Institute408 enrolled5 locationsNCT06888817
Recruiting
Not Applicable

Evaluating the Implementation and Impact of Standard-of-care Delivered Oncology Financial Navigation

OncologyFinancial ToxicityCounseling
University of Alabama at Birmingham40 enrolled1 locationNCT07281287
Recruiting
Early Phase 1

Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy

Immune Effector Cell Associated Hematotoxicity
Institute of Hematology & Blood Diseases Hospital, China15 enrolled1 locationNCT07212335